Skip to main content
  • Saved

made a Post

COVID-19 vaccination and HIV-1 acquisition

COVID-19 vaccination and HIV-1 acquisition

Source :

Susan P Buchbinder and colleagues1 express concern that COVID-19 vaccines utilising replication-defective adenovirus vectors of human serotype 5 (HAdV-5) might increase the risk of HIV-1 acquisition. Such concern has prompted hesitancy to deploy available, safe, and efficacious adenovirus-based COVID-19 vaccines in countries with high HIV-1 incidence.

Conclusion: Due vigilance and monitoring of adverse events, including HIV-1 infection rates, are absolutely crucial in the pandemic response and the roll-out of vaccines, but still, we would urge global health authorities to license and distribute any efficacious and safe vaccines that are available especially while access to COVID-19 vaccines in low-income countries remains insufficient.